Esophageal Cancer Clinical Trial

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Summary

A clinical trial to determine the effectiveness and safety of AUY922 compared to other drugs known to be effective against gastric cancer in second line therapy for patients who have failed one line of chemotherapy.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Radiologically confirmed advanced gastric cancer
One previous line of chemotherapy
Progressive disease
One measurable lesion
Blood tests within protocol ranges
(WHO) Performance Status ≤ 1
Able to sign informed consent

Exclusion Criteria:

No symptomatic brain metastases
No coumarin type anticoagulants
No liver or kidney disease
No impaired heart function
No pregnant or lactating women

Other protocol-defined inclusion/exclusion criteria may apply

Study is for people with:

Esophageal Cancer

Phase:

Phase 2

Estimated Enrollment:

68

Study ID:

NCT01084330

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 35 Locations for this study

See Locations Near You

USC/Kenneth Norris Comprehensive Cancer Center USC/Norris
Los Angeles California, 90033, United States
University of California at Los Angeles Dept. of UCLA (4)
Los Angeles California, 90095, United States
Horizon Oncology Center
Lafayette Indiana, 47905, United States
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Dept. of SKCC @ JHU
Baltimore Maryland, 21287, United States
Clinical Research Alliance Dept.ofArenaOncologyAssoc(2)
Lake Success New York, 11042, United States
Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology
Dallas Texas, 75246, United States
Tyler Cancer Center Dept.ofTylerCancerCtr. (2)
Tyler Texas, 75702, United States
Novartis Investigative Site
Adelaide South Australia, 5000, Australia
Novartis Investigative Site
Montreal Quebec, H3G 1, Canada
Novartis Investigative Site
Bordeaux Cedex , 33075, France
Novartis Investigative Site
Lyon Cedex , 69373, France
Novartis Investigative Site
Toulouse Cedex 9 , 31059, France
Novartis Investigative Site
Erlangen , 91054, Germany
Novartis Investigative Site
Ulm , 89081, Germany
Novartis Investigative Site
Genova GE, 16132, Italy
Novartis Investigative Site
Modena MO, 41100, Italy
Novartis Investigative Site
Pisa PI, 56100, Italy
Novartis Investigative Site
Roma RM, 00168, Italy
Novartis Investigative Site
Napoli , 80131, Italy
Novartis Investigative Site
Suwon Gyeonggi-do, 442-7, Korea, Republic of
Novartis Investigative Site
Suwon Gyeonggi-do, 443-3, Korea, Republic of
Novartis Investigative Site
Seoul Korea, 05505, Korea, Republic of
Novartis Investigative Site
Utrecht , 3584C, Netherlands
Novartis Investigative Site
Moscow , 11547, Russian Federation
Novartis Investigative Site
Moscow , 12912, Russian Federation
Novartis Investigative Site
Singapore , 16961, Singapore
Novartis Investigative Site
Bellinzona , 6500, Switzerland
Novartis Investigative Site
Kuei-Shan Chiang Taoyuan/ Taiwan ROC, 33305, Taiwan
Novartis Investigative Site
Tainan , 704, Taiwan
Novartis Investigative Site
Taipei , 10048, Taiwan
Novartis Investigative Site
Taipei , , Taiwan
Novartis Investigative Site
Ankara , 06500, Turkey
Novartis Investigative Site
Surrey England, GU2 7, United Kingdom
Novartis Investigative Site
Sutton Surrey, SM2 5, United Kingdom
Novartis Investigative Site
Glasgow , G12 0, United Kingdom
Novartis Investigative Site
Leicester , LE7 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 2

Estimated Enrollment:

68

Study ID:

NCT01084330

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider